Endothelial Erg Regulates Expression of Pulmonary Lymphatic Junctional and Inflammation Genes in Mouse Lungs Impacting Lymphatic Transport

Why It Matters

The study connects ERG deficiency in lung lymphatics to heightened inflammation and altered fluid dynamics, offering a mechanistic bridge to idiopathic pulmonary fibrosis and potential therapeutic avenues.

Key Takeaways

• ERG loss in lung LECs triggers inflammatory gene program
• Erg‑CKO mice show enhanced interstitial lymphatic fluid transport
• Junctional gene expression drops, increasing LEC permeability
• Single‑cell analysis reveals altered LEC communication pathways
• Findings link lymphatic ERG to pulmonary fibrosis mechanisms

Pulse Analysis

Endothelial transcription factor ERG has long been recognized as a master regulator of vascular homeostasis, governing barrier integrity, permeability, and inflammatory responses. In the pulmonary context, ERG’s enrichment across capillary, venous, and arterial endothelium positions it as a sentinel against dysregulated fluid exchange. Recent preclinical work extends this paradigm to lymphatic endothelial cells, suggesting that ERG’s influence spans the entire vascular tree and may be critical for maintaining lung fluid balance, especially under stress conditions such as fibrosis.

The investigators employed a Prox1‑driven, inducible Erg knockout model to isolate the impact of ERG loss within lung LECs. Microarray profiling, flow cytometry, and qPCR collectively demonstrated a shift toward a pro‑inflammatory, pro‑lymphangiogenic phenotype. Functional FITC‑dextran tracing confirmed that Erg‑deficient mice transport interstitial lymphatic fluid more rapidly to axial lymph nodes, implicating compromised junctional complexes. Single‑cell transcriptomics pinpointed down‑regulation of key adhesion molecules and highlighted perturbed CellChat‑derived signaling networks that facilitate trans‑endothelial migration and endothelial‑to‑mesenchymal transition.

These findings carry weight for idiopathic pulmonary fibrosis (IPF), where lymphatic dysfunction and chronic inflammation exacerbate disease progression. By linking ERG deficiency to both molecular and physiological derangements in pulmonary lymphatics, the study opens a pathway for therapeutic exploration—either through restoring ERG activity or targeting downstream effectors of the disrupted communication circuits. Future research should validate these mechanisms in human IPF tissue and assess whether pharmacologic modulation of ERG‑dependent pathways can ameliorate lymphatic leakage and fibrotic remodeling, potentially reshaping treatment strategies for a condition with limited options.